scholarly article | Q13442814 |
P356 | DOI | 10.1093/JAC/DKW409 |
P698 | PubMed publication ID | 27707992 |
P50 | author | Sarah Hendrickx | Q94593639 |
P2093 | author name string | E Eberhardt | |
L Maes | |||
G Caljon | |||
J Beyers | |||
A Mondelaers | |||
M Van den Kerkhof | |||
P2860 | cites work | Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol | Q28483977 |
Leishmania donovani develops resistance to drug combinations | Q28484463 | ||
Paromomycin | Q34864208 | ||
An update on pharmacotherapy for leishmaniasis | Q34945204 | ||
Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challenges | Q34953705 | ||
Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients | Q35095252 | ||
Use of antimony in the treatment of leishmaniasis: current status and future directions | Q35377767 | ||
In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis--status of newly introduced drugs | Q36450807 | ||
A Replicative In Vitro Assay for Drug Discovery against Leishmania donovani | Q36933516 | ||
Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani | Q37712969 | ||
In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent | Q39444290 | ||
In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences | Q41844113 | ||
Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. | Q46191825 | ||
Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum | Q46921246 | ||
Intracellular amastigote replication may not be required for successful in vitro selection of miltefosine resistance in Leishmania infantum. | Q53541333 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Leishmania donovani | Q1950752 |
Leishmania infantum | Q1950789 | ||
P304 | page(s) | 428-430 | |
P577 | publication date | 2016-10-05 | |
P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
P1476 | title | In vitro 'time-to-kill' assay to assess the cidal activity dynamics of current reference drugs against Leishmania donovani and Leishmania infantum | |
P478 | volume | 72 |
Q57190987 | Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis |
Q88552967 | Fragment-Based Phenotypic Lead Discovery: Cell-Based Assay to Target Leishmaniasis |
Q50051086 | In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series. |
Q52673716 | Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages. |
Q89719497 | Topical Amphotericin B Semisolid Dosage Form for Cutaneous Leishmaniasis: Physicochemical Characterization, Ex Vivo Skin Permeation and Biological Activity |
Search more.